E-mail this page Printer Friendly Version RSS E-mail Alerts View contacts Download Financial Tear Sheet 

Investor Relations

DGX (Common Stock)
ExchangeNYSE (US Dollar)
Change (%) Stock is Up 0.64 (0.73%)
Intraday High$89.07
Intraday Low$87.39
Data as of 12/11/18 4:02 p.m. ET
Minimum 20 minute delay
Refresh quote
Webcast ImageWebcast - Replay
Quest Diagnostics 2018 Investor Day
11/29/18 at 8:00 a.m. ET
Quest Diagnostics 2018 Investor Day
Thursday, November 29, 2018 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Headlines More >
PAMA is Here, But Most Hospitals are Unaware of Its Impact, Study Finds
SECAUCUS, N.J., Dec. 4, 2018 /PRNewswire/ -- Nearly 80 percent of hospital executives surveyed are not at all familiar, or only somewhat familiar, with the Protecting Access to Medicare Act (PAMA) and its impact on hospitals, according to a survey conducted by Modern Healthcare Custom Media on behalf of Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Nearly 80 percent of executives surveyed lacked significa... 
Quest Diagnostics to Build Flagship Laboratory at Visionary Campus in Clifton, New Jersey to Empower Better Health for Patients in Seven States
New lab to be the company's largest in country with more than 1,100 employees, featuring innovative design, automation and expanded capacity SECAUCUS, N.J., Nov. 28, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it will build a flagship laboratory in Clifton, N.J. to enhance the diagnostic information services it provides to over 40 million people in New Jersey, New York, Pennsylvania, Mar... 
Quest Diagnostics to Discuss Strategic Growth Drivers and Financial Outlook at 2018 Investor Day
-- Provides outlook for 2019-2022, extending the company's targeted 3-5% revenue compound annual growth rate (CAGR) and updating its adjusted earnings goal to a 4-6% CAGR -- Raises dividend by 6% to an annual rate of $2.12 per share, the company's eighth dividend increase since 2011 -- Updates outlook for full year 2018. Reported revenues now expected to be approximately $7.57 billion. Reported diluted EPS now expected to be greater than $5.34 and adjusted diluted EPS excluding amortizatio... 
Quest Diagnostics to Acquire the Laboratory Services Business of Boyce and Bynum Pathology Laboratories, Expanding Diagnostic Innovation in the Midwest
Transaction aims to provide a broader range of clinical and pathology diagnostic services to patients, hospitals and physicians throughout Missouri and surrounding Midwestern states SECAUCUS, N.J. and COLUMBIA, Mo., Nov. 27, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology L... 
Upcoming EventsMore >
There are currently no events scheduled.
Contact Us
Company Calendar
December 2018?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
52 Week High

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.